Document is current
Any future updates will be listed below
-
Authors
Woodie, Brad R. https://orcid.org/0000-0002-7481-5216
Mukenge, Megan M.
Feldman, Steven R.
Fleischer, Alan B. Jr.
- License Information
-
More Information
Article History
Received: 10 June 2025
Revised: 29 July 2025
Accepted: 9 February 2026
First Online: 13 March 2026
Declarations
:
: Steven Feldman has received research, speaking and/or consulting support from Eli Lilly and Company, GlaxoSmithKline/Stiefel, AbbVie, Janssen, Alovtech, vTv Therapeutics, Bristol-Myers Squibb, Samsung, Pfizer, Boehringer Ingelheim, Amgen, Dermavant, Arcutis, Novartis, Novan, UCB, Helsinn, Sun Pharma, Almirall, Galderma, Leo Pharma, Mylan, Celgene, Ortho Dermatology, Menlo, Merck & Co, Qurient, Forte, Arena, Biocon, Accordant, Argenx, Sanofi, Regeneron, the National Biological Corporation, Caremark, Teladoc, BMS, Ono, Micreos, Eurofins, Informa, UpToDate, Verrica, and the National Psoriasis Foundation. He is founder and part owner of Causa Research and holds stock in Sensal Health. Alan Fleischer is a consultant for Bluefin and Incyte (fees). He is an investigator for Amgen, Avalo, Bayer, Biogen, CellDex, Galderma, Incyte, Leo, and UCB (research support). He is a speaker for Imedic Healthcare Solutions (Hyderabad, India). Brad Woodie and Megan Mukenge have no conflicts of interest to declare.
: Not needed, as this was non-human subject research.
: Not applicable, as this was non-human subject research.
